Latest news with #Bio-Techne
Yahoo
07-08-2025
- Business
- Yahoo
Stocks making big moves yesterday: Bloomin' Brands, Bio-Techne, Snap, Grocery Outlet, and Paramount
Check out the companies making headlines yesterday: Bloomin' Brands (NASDAQ:BLMN): Restaurant company Bloomin' Brands (NASDAQ:BLMN) fell by 27.6% on Wednesday after the company reported declining profit margins and slashed its full-year earnings forecast, citing rising costs. See our full article here. Is now the time to buy Bloomin' Brands? Access our full analysis report here, it's free. Bio-Techne (NASDAQ:TECH): Life sciences company Bio-Techne (NASDAQ:TECH) fell by 6.5% on Wednesday after the company reported its fourth-quarter fiscal 2025 results, which included a significant net loss driven by a large impairment charge. See our full article here. Is now the time to buy Bio-Techne? Access our full analysis report here, it's free. Snap (NYSE:SNAP): Social network Snapchat (NYSE: SNAP) fell by 17.7% on Wednesday after the company reported disappointing second-quarter financial results, driven by a revenue miss and a critical error on its advertising platform. See our full article here. Is now the time to buy Snap? Access our full analysis report here, it's free. Grocery Outlet (NASDAQ:GO): Discount grocery store chain Grocery Outlet (NASDAQ:GO) rose by 38.9% on Wednesday after the company reported second-quarter earnings that surpassed analyst expectations and raised its full-year profit forecast. See our full article here. Is now the time to buy Grocery Outlet? Access our full analysis report here, it's free. Paramount (NASDAQ:PARA): Multinational media and entertainment corporation Paramount (NASDAQ:PARA) fell by 6.5% on Wednesday after Needham advised investors to 'move to the sidelines' due to uncertainty surrounding its upcoming merger with Skydance Media. See our full article here. Is now the time to buy Paramount? Access our full analysis report here, it's free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
06-08-2025
- Business
- Yahoo
Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 3.5% year on year to $317 million. Its non-GAAP profit of $0.53 per share was 6.1% above analysts' consensus estimates. Is now the time to buy Bio-Techne? Find out in our full research report. Bio-Techne (TECH) Q2 CY2025 Highlights: Revenue: $317 million vs analyst estimates of $314.7 million (3.5% year-on-year growth, 0.7% beat) Adjusted EPS: $0.53 vs analyst estimates of $0.50 (6.1% beat) Adjusted EBITDA: $115.6 million vs analyst estimates of $110.2 million (36.5% margin, 4.9% beat) Operating Margin: -7.5%, down from 15% in the same quarter last year Free Cash Flow Margin: 29.4%, up from 18.8% in the same quarter last year Organic Revenue rose 3% year on year (0.7% in the same quarter last year) Market Capitalization: $8.57 billion "Bio-Techne delivered a solid fourth quarter that was in-line with our expectations, despite ongoing market uncertainty," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. Company Overview With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, Bio-Techne's 10.5% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Bio-Techne's recent performance shows its demand has slowed as its annualized revenue growth of 3.6% over the last two years was below its five-year trend. Bio-Techne also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Bio-Techne's organic revenue averaged 3.1% year-on-year growth. Because this number aligns with its two-year revenue growth, we can see the company's core operations (not acquisitions and divestitures) drove most of its results. This quarter, Bio-Techne reported modest year-on-year revenue growth of 3.5% but beat Wall Street's estimates by 0.7%. Looking ahead, sell-side analysts expect revenue to grow 5.1% over the next 12 months, an improvement versus the last two years. This projection is above the sector average and suggests its newer products and services will spur better top-line performance. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Bio-Techne has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 20.6%. Analyzing the trend in its profitability, Bio-Techne's operating margin decreased by 17.1 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 17.9 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, Bio-Techne generated an operating margin profit margin of negative 7.5%, down 22.5 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Bio-Techne's remarkable 11.2% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded. In Q2, Bio-Techne reported adjusted EPS at $0.53, up from $0.49 in the same quarter last year. This print beat analysts' estimates by 6.1%. Over the next 12 months, Wall Street expects Bio-Techne's full-year EPS of $1.93 to grow 7.1%. Key Takeaways from Bio-Techne's Q2 Results It was good to see Bio-Techne narrowly top analysts' organic revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. Overall, this print had some key positives. Investors were likely hoping for more, and shares traded down 2.2% to $53.40 immediately after reporting. Is Bio-Techne an attractive investment opportunity right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Business Wire
15-07-2025
- Business
- Business Wire
Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology
WOBURN, Mass.--(BUSINESS WIRE)--Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio's groundbreaking SPEAR UltraDetect™ immunoassays, focusing initially on the neurology research market. The introductory SPEAR UltraDetect offering targets biomarkers pivotal to neurodegenerative diseases, such as phosphorylated tau 231 (pTau 231), phosphorylated tau 217 (pTau 217), glial fibrillary acidic protein (GFAP), and neurofilament light (Nf‑L). This partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding round in 2024. Early detection of protein biomarkers is essential for understanding historically challenging disease mechanisms, developing early interventions, and advancing clinical trials. Spear Bio's Successive Proximity Extension Amplification Reaction (SPEAR) platform, based on breakthrough technology licensed from Harvard University, and amplified using conventional qPCR instrumentation, offers sensitivity two to three orders of magnitude higher than current immunoassay platforms. "Partnering with Spear Bio marks an exciting step in our mission to advance biomarker detection in neurodegenerative disease research," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "By leveraging Bio-Techne's global reach and immunoassay expertise with Spear Bio's ultrasensitive technology, we are equipping researchers with innovative tools to detect and study critical biomarkers with unmatched precision and sensitivity." With Bio-Techne's global reach, Spear Bio is well-positioned to accelerate the deployment of its next-generation assay technology, enabling researchers to detect biomarkers in historically challenging conditions. Spear Bio's initial focus is neurodegenerative diseases, with the technology relevant for inflammation, oncology and additional fields. In addition, Spear Bio's advanced detection technology expands applications in high-growth markets, including early neurodegenerative disease diagnosis, enhancing patient access to critical interventions. 'Our strategic partnership with Bio-Techne represents a transformative opportunity for neurodegenerative disease research,' said Feng Xuan, PhD, Founder and CEO of Spear Bio. 'By combining Bio-Techne's global distribution network and market leadership with Spear Bio's next-generation immunoassay technology, we are empowering researchers worldwide to investigate earlier disease mechanisms, improve patient stratification in clinical trials, and accelerate the development of new treatments for neurological disorders.' This partnership underscores the promise of Spear Bio's SPEAR technology and reinforces Bio-Techne's commitment to advancing biomarker detection. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. About Spear Bio Founded in 2021 and headquartered in Woburn, Massachusetts, Spear Bio is dedicated to its mission of revolutionizing biomarker research and diagnostics through innovation and accessibility. Leveraging its unique homogeneous assay format, SPEAR technology consistently delivers highly sensitive and precise protein measurements. Spear Bio envisions a future where high-performance assays democratize access to critical insights, accelerating progress in research and medicine worldwide. To learn more about the company, please visit the Spear Bio website.
Yahoo
03-07-2025
- Business
- Yahoo
1 S&P 500 Stock to Research Further and 2 to Keep Off Your Radar
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition. Picking the right S&P 500 stocks requires more than just buying big names, and that's where StockStory comes in. That said, here is one S&P 500 stock that could deliver good returns and two best left off your watchlist. Market Cap: $112.8 billion Originally selling Japanese Onitsuka Tiger sneakers as Blue Ribbon Sports, Nike (NYSE:NKE) is a global titan in athletic footwear, apparel, equipment, and accessories. Why Do We Think NKE Will Underperform? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Sales are projected to tank by 1.3% over the next 12 months as its demand continues evaporating Eroding returns on capital suggest its historical profit centers are aging Nike is trading at $76.61 per share, or 44.7x forward P/E. Read our free research report to see why you should think twice about including NKE in your portfolio, it's free. Market Cap: $8.34 billion With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development. Why Do We Think Twice About TECH? Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion Revenue base of $1.21 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale Free cash flow margin shrank by 8.2 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive Bio-Techne's stock price of $53.18 implies a valuation ratio of 25.5x forward P/E. To fully understand why you should be careful with TECH, check out our full research report (it's free). Market Cap: $233.3 billion With roots dating back to 1888 when founder Dr. Wallace Abbott began producing precise, dosage-form medications, Abbott Laboratories (NYSE:ABT) develops and sells a diverse range of healthcare products including medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. Why Is ABT on Our Radar? Scale advantages are evident in its $42.34 billion revenue base, which provides operating leverage when demand is strong Robust free cash flow margin of 16.6% gives it many options for capital deployment Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures At $134.23 per share, Abbott Laboratories trades at 25.2x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-06-2025
- Business
- Yahoo
Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development
Bio-Techne Corporation (NASDAQ:TECH) is one of the best S&P 500 stocks with huge upside potential. On June 24, Bio-Techne Corporation announced a distribution agreement with the US Pharmacopeia/USP. The collaboration allows Bio-Techne to sell USP monoclonal antibody/mAb and recombinant adeno-associated virus/AAV reference standards alongside its analytical solutions, like the Maurice system, to support the global development of monoclonal antibody and gene therapy products. Over 160 antibody therapies targeting ~100 diseases have been approved worldwide. The expiration of mAb patent protections and the emergence of biosimilar versions further emphasize the need for rigorous testing of critical quality attributes throughout the development and manufacturing processes for product safety and efficacy. A team of scientists wearing lab coats and protective eyewear in a research laboratory, intently looking into microscopes and analyzing results. The USP mAb and AAV reference standards are compatible with Bio-Techne's analytical instruments, such as the MauriceFlex system. By combining these standards with Bio-Techne's rapid, user-friendly, and multi-functional analytics, therapy manufacturers can achieve reliable, efficient, and integrated characterization for purity, charge, size, and identity applications for complex biologics, from the initial development phases through to product release. Bio-Techne Corporation (NASDAQ:TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. While we acknowledge the potential of TECH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
